share_log

双成药业(002693.SZ):本次交易的审计、评估工作尚未完成

Hainan Shuangcheng Pharmaceuticals (002693.SZ): The audit and evaluation work for this trade has not yet been completed.

Gelonghui Finance ·  Nov 20 04:02

Gelonghui, November 20th丨Hainan Shuangcheng Pharmaceuticals (002693.SZ) announced that the company's stock trading price had a cumulative closing price increase deviation value exceeding 20% for three consecutive trading days from November 18, 2024, to November 20, 2024, which is classified as an abnormal fluctuation in stock trading. The company is planning a major asset restructuring matter, intending to acquire 100% of the shares of Aola held by 25 trading partners including Aola Investment and Win Aiming through issuing shares and paying cash, and also plans to issue shares to no more than 35 specific investors to raise supporting funds. The audit and evaluation work for this transaction has not yet been completed, the specific transaction price has not been determined, and it still requires further review by the company's board of directors and approval at the company's shareholders' meeting, as well as approval from relevant regulatory agencies before it can be officially implemented. There remains some uncertainty regarding whether approval can be obtained.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment